Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 69, Issue -, Pages 393-399Publisher
ELSEVIER
DOI: 10.1016/j.ijbiomac.2014.05.067
Keywords
Paclitaxel; Nanoparticles; Poloxamer; Cytotoxicity; Drug delivery
Funding
- Department of Science and Technology, Government of India
- Indian Council of Medical Research, New Delhi [3/1/3/JRF-2010/HRD-79]
- Department of Science and Technology, Government of India [IF110529, IF110600]
Ask authors/readers for more resources
This investigation described the development of novel PLGA:poloxamer blend nanoparticles for intravenous administration of paclitaxel in order to limit the cremophor-associated adverse effects. The developed formulation was well-characterized using various techniques including scanning electron microscopy, transmission electron microscopy, Fourier transform infrared spectroscopy and differential scanning calorimetry. The nanoparticles had an average particle size around 180 nm and zeta potential of -22.7 mV. The in vitro release study of nanoparticles exhibited biphasic release pattern. The non-hemolytic potential of the nanoparticles indicated the suitability of the developed formulation for intravenous administration. The PLGA:poloxamer blend nanoparticles showed significantly improved cytotoxicity in cell lines (MCF-7 and Colo-205), as compared to free drug. Further, the developed formulation was stable under the accelerated storage conditions. In conclusion, the results indicated that the developed polymeric formulation is a novel and potential alternative for the paclitaxel delivery. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available